NASDAQ$EPIX
Essa Pharma Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Essa Pharma reported financial results for the fiscal third quarter ended June 30, 2023 and provided a corporate update.
ESSA Pharma reported its financial results for the third quarter ended June 30, 2023. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
- Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) is expected to complete in the third calendar quarter of 2023.
- A randomized Phase 2 part of the study is expected to be initiated after completing Phase 1.
- ESSA entered into a clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate).
- Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients is ongoing.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$0
Forward guidance
ESSA Pharma's forward-looking statements include the completion of the Phase 1 combination study with enzalutamide, initiation of the randomized Phase 2 part of the study, and the Company’s expected cash runway into 2025.
Tailwinds
- Completion of the Phase 1 combination study with enzalutamide.
- Initiation of the randomized Phase 2 part of the study.
- Enrollment in the monotherapy and combination studies.
- Assessment of anti-tumor activity in the Phase 2 combination study.
- The Company’s expected cash runway into 2025.
Headwinds
- Risks associated with obtaining positive results of clinical trials.
- Risks associated with obtaining necessary regulatory approvals.
- General business, market and economic conditions.
- Uncertainties in medical, scientific, business, economic, competitive, political and social factors.
- Potential differences between actual results and those expressed or implied in forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q3 2023
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro